Pharma & Bio
Lifestyle
Broker Call Boosts Qurient; AbClon and L&C Bio Rebound on Rights Offering [K-Bio Pulse]
South Korea’s KOSDAQ market closed higher on Tuesday, supported by net buying from foreign and institutional investors, while most pharmaceutical and biotechnology stocks also gained. Qurient, AbClon,…
Lifestyle
20% Surge on a Single Report... Qurient Co., Ltd. and AbClon Inc. Soar, L&C BIO Reevaluated Following Rights Offering [Bio Spotlight]
The KOSDAQ market showed strength, driven by net buying from both foreign and institutional investors, and most stocks in the pharmaceutical and biotech sectors also closed higher. In particular, Quri…
Technology
Dot CEO Kim Ju-yoon, Who Has Secured Partnerships with Google, Apple, and Microsoft: "Expanding Surgical Robot Business... Currently Collaborating with Major Companies"
Dot, a social venture that commercialized the world’s first tactile display, is expanding its business beyond devices for the visually impaired into the surgical robotics market. Kim Ju-yun, CEO of Do…
KOSDAQ
DEEPNOID Inc. and Peptron, Inc. Rise… L&C BIO Weakens on Capital Increase [Bio Spotlight]
On the 3rd, the domestic pharmaceutical and biotech sector saw a tailwind thanks to the KOSDAQ’s strong performance. Buying pressure surged on the KOSDAQ that day, triggering the 16th “KOSDAQ Buy Side…
KOSDAQ
Deepnoid and Peptron Hit Daily Limit; L&C Bio Falls on Rights Offering [K-Bio Pulse]
South Korea’s pharmaceutical and biotechnology sector received a boost on Aug. 3 as the KOSDAQ market posted strong gains. Buying momentum intensified, triggering the 16th KOSDAQ buy-side circuit brea…
Technology
All 8 Pharmaceutical and Biotech Companies Listed This Year Traded Below Their Offering Price… Will IPOs in the Second Half Also See Lower Valuations?
The stock prices of all eight pharmaceutical, biotech, and healthcare companies that listed on KOSDAQ this year are trading below their initial public offering (IPO) prices. Although these companies r…
Technology
[K-Bio Fund, Part 2] CEO Hwang Man-soon, Who Leads the Phase 3 Clinical Trial Fund: "Aiming for First Investment This Year… Focus on Rare Disease Pipeline"
“We expect to complete the formation of the fund during the fourth quarter and make our first investment by the end of the year. We’ve been receiving inquiries from various sources ever since the asse…
Technology
[K-Bio Fund, Part 1] From the National Growth Fund to a 1 Trillion Mega Fund… The Government Fills the 'Death Valley'
Government policy funds are being channeled through a two-track approach to address the late-stage clinical funding gap, which has been the biggest challenge facing the domestic pharmaceutical and bio…
Technology
A Closer Look at U.S. CPT Code Requirements… Raises Questions About Rokit Healthcare’s Potential to Benefit
(Graphic: ChatGPT)
While Rokit Healthcare expects to benefit from the reorganization of U.S. medical procedure codes related to regenerative medicine, a closer look at the detailed requirements of…
Technology
Biotech Stocks Rally as the Market Rebounds; Orum Therapeutics Jumps 18% [K-Bio Pulse]
On July 31, South Korean pharmaceutical and biotech stocks rose across the board as the domestic stock market rebounded, with bargain hunting returning to battered growth and biotech stocks. While man…